rs2359612
Orientation | plus |
Stabilized | plus |
Geno | Mag | Summary |
---|---|---|
(A;A) | 0 | common in clinvar |
Make rs2359612(A;G) |
Make rs2359612(G;G) |
Reference | GRCh38 38.1/141 |
Chromosome | 16 |
Position | 31092475 |
Gene | VKORC1 |
is a | snp |
is | mentioned by |
dbSNP | rs2359612 |
dbSNP (classic) | rs2359612 |
ClinGen | rs2359612 |
ebi | rs2359612 |
HLI | rs2359612 |
Exac | rs2359612 |
Gnomad | rs2359612 |
Varsome | rs2359612 |
LitVar | rs2359612 |
Map | rs2359612 |
PheGenI | rs2359612 |
Biobank | rs2359612 |
1000 genomes | rs2359612 |
hgdp | rs2359612 |
ensembl | rs2359612 |
geneview | rs2359612 |
scholar | rs2359612 |
rs2359612 | |
pharmgkb | rs2359612 |
gwascentral | rs2359612 |
openSNP | rs2359612 |
23andMe | rs2359612 |
SNPshot | rs2359612 |
SNPdbe | rs2359612 |
MSV3d | rs2359612 |
GWAS Ctlg | rs2359612 |
GMAF | 0.4986 |
Max Magnitude | 0 |
? | (A;A) (A;G) (G;G) | 28 |
---|---|---|
|
[PMID 22321278] [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy]
[PMID 17048007] Association of warfarin dose with genes involved in its action and metabolism.
[PMID 17549303] Functional promoter polymorphism in the VKORC1 gene is no major genetic determinant for coronary heart disease in Northern Germans.
[PMID 18252229] Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.
[PMID 18466099] Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.
[PMID 18523153] Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement.
[PMID 18559094] Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction.
[PMID 18574025] The largest prospective warfarin-treated cohort supports genetic forecasting.
[PMID 18752379] Warfarin pharmacogenetics.
[PMID 18841283] Single nucleotide polymorphisms in the VKORC1 gene and the risk of stroke in the Southern German population.
[PMID 18855533] VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans.
[PMID 19074728] Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy.
[PMID 19228618] Estimation of the warfarin dose with clinical and pharmacogenetic data.
[PMID 19300499] A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.
[PMID 19738376] Pharmacogenetic testing for guiding de novo phenprocoumon therapy in stroke patients.
[PMID 19955245] Warfarin sensitivity genotyping: a review of the literature and summary of patient experience.
[PMID 22178823] [Distribution of variant alleles association with warfarin pharmacokinetics and pharmacodynamics in the Han population in China].
[PMID 26040031] [Association of allelic polymorphisms of genes matrix Gla-protein system with ischemic atherothrombotic stroke]
ClinVar | |
---|---|
Risk | rs2359612(G;G) |
Alt | rs2359612(G;G) |
Reference | Rs2359612(A;A) |
Significance | Drug-response |
Disease | warfarin response - Dosage |
Variation | info |
Gene | VKORC1 |
CLNDBN | warfarin response - Dosage |
Reversed | 0 |
HGVS | NC_000016.9:g.31103796A>G |
CLNSRC | PharmGKB Clinical Annotation |
CLNACC | RCV000211406.1, |
[PMID 27889279] Vitamin K epoxide reductase expression and prostate cancer risk.